Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Analiza EEG do obiektywnej oceny senności (MEEGASAFE)

16 września 2026 zaktualizowane przez: Physip S.A

Analiza EEG do obiektywnej oceny wtórnej nadsenności w celu ograniczenia ryzyka przypadkowego

The objective of this clinical study is to develop solutions for the evaluation and management of drowsiness, based on 2 EEG sensors only, aiming at reducing the risk of accidents related to secondary hypersomnolence (sleepiness induced by sleep restriction or abnormal sleep/wake cycle). This project will allow a better understanding of the determinants of drowsiness and its impact on cognitive performance and the development of methods and models for the evaluation and prediction of cognitive performance deficit related to sleepiness. The secondary hypersomnolence will be objectified by continuous EEG recording and analysed by visual reading according to Objective Sleepiness Scale (OSS) criteria and automatically analyzed using the MEEGAWAKE algorithm (developed by PHYSIP). The level of secondary hypersomnolence will be modified by varying the duration and maintening of prior sleep or the sleep timing. The ability to stay awake will be measured by the maintenance of wakefulness test (MWT). Subjective sleepiness and mind wandering will be measured before and/or after all measurements. Simulated driving task, maintenance of wakefulness tests and several cognitive tasks to measure sustained attention, alertness, selective attention will be performed every 4 hours.

Przegląd badań

Status

Aktywny, nie rekrutujący

Warunki

Szczegółowy opis

Chronotype and general tendency to daydream in daily life will be evaluated at the inclusion visit. Healthy volunteers will be placed in sleep deprivation patterns that will modify the level of secondary hypersomnolence. These patterns correspond to sleep deprivation caused by work schedules usually observed: shift work (SDP1) or night on-call (SDP2). shift work will be simulated by total sleep deprivation for 24 hours (comparable to the first day of a night worker) followed by early morning sleep, and an extended 17 hours wakefulness (comparable to second day of night shift). Secondary hypersomnolence will be assessed throughout prolonged awakenings (24 hours + 17 hours). The night on-call will be simulated by two half-hour awakenings during the nocturnal sleep. Hypersomnolence will be measured within 17 hours of wakefulness following this sleep fragmentation. The sleep history (quantity and quality of sleep) will be evaluated by actigraphy + ambulatory polysomnography (1 day before the experiment) and 2 polysomnographies in the laboratory during the experiment. Polysomnography recordings will be visually and automatically analyzed by the ASEEGA algorithm. Ambulatory recordings are automatically analyzed by ASEEGA. Throughout these sleep deprivation patterns, electrophysiological variables (EEG, EOG and EMG) will be continuously recorded in order to identify objective drowsiness states determined visually using the OSS or automatically by the MEEGAWAKE algorithm. Subjective sleepiness scale, Mind wandering scale, maintenance of wakefulness tests (MWT, electrophysiological test) and cognitive tests will be repeated, every 4hr, throughout the sleep deprivation patterns in order to determine abilities to stay awake, driving performance, sustained and selective attention, vigilance.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

40

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

      • Bordeaux, Francja, 33076
        • CHU bordeaux

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

20 lat do 60 lat (Dorosły)

Akceptuje zdrowych ochotników

Tak

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • BMI between 18 and 27,
  • With a score on the PHQ-4 scale less than or equal to 2 for scores A (Anxiety) and D (Depression),
  • Subjects with no complaints of excessive daytime sleepiness (total ESS score <11),
  • Non-professional drivers,
  • Subjects who have held their driving license for at least one year,
  • Subjects affiliated to a social security scheme,
  • Subjects able to understand the study,
  • Subjects available to come to the 3 visits required by the study,
  • Free, informed and written consent signed

Exclusion Criteria:

  • Pathologies that can induce excessive daytime sleepiness: untreated narcolepsy or idiopathic hypersomnia, untreated restless legs syndrome, untreated periodic leg movement syndrome,
  • Chronic insomnia disorder,
  • Excessive alcohol consumption (> 2 glasses per day) during the last 6 months,
  • Excessive consumption of coffee, tea or cola-type caffeinated beverages (> 5 cups/day),
  • Severe pathologies involving the vital prognosis in the short term,
  • Uncontrolled endocrine pathologies (dysthyroidism, diabetes),
  • All progressive cardiac pathologies, treated or untreated,
  • All progressive neurological conditions treated or not (brain tumor, epilepsy, migraine, stroke, sclerosis, myoclonus, chorea, neuropathy, muscular dystrophies, myotonic dystrophy, etc.),
  • Substance dependence,
  • Shift workers or night workers who have performed on-call or on-call duty in the last 72 hours,
  • Patients taking psychotropic drugs (antidepressants, antihistamines),
  • Long-term treatment with benzodiazepines and z-drugs,
  • Patients on cardiotropic,
  • Deprived of liberty by a judicial or administrative decision,
  • Pregnant or breastfeeding woman,
  • Subject under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Podstawowa nauka
  • Przydział: Nie dotyczy
  • Model interwencyjny: Zadanie dla jednej grupy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Sleep deprivation

healthy volunteers

Sleep deprivation patterns 1 (SDP1) ; total sleep deprivation for 24 hours followed by early morning sleep and an extended 17 hours wakefulness. Sleep deprivation patterns 2 (SDP2) : Sleep interrupted by two half-hour awakenings

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Change in Objective Sleepiness Scale (OSS) during extended wakefulness
Ramy czasowe: Once every 4 hours during SDP1 and SDP2 wakefulness

OSS is based on the visual analysis of electrophysiological variables (EEG (C4, O2, C3, P3), 1 vertical EOG and 1 horizontal EOG).

Each state of drowsiness (score) corresponds to a specific EEG activity accompanied by well-differentiated blinking and eye movements

Once every 4 hours during SDP1 and SDP2 wakefulness

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Change in Karolinska sleepiness scale (KSS) during extended wakefulness
Ramy czasowe: 12 assessments every 4 hours during SDP1 and SDP2 wakefulness

The KSS is a self-administered questionnaire that measures, on a 10 point Likert scale ranging from=1 to "fully awake" to 10 ="extremely drowsy". This measure has very good external validity on EEG synchronization measures and on the cognitive and behavioral performance of subject in relation to his or her ability to maintain wakefulness.

12 assessments every 4 hours during SDP1 and SDP2 wakefulness
Change in sleep onset mesured by Maintenance of Wakefulness Test (MWT) during extended wakefulness
Ramy czasowe: Once every 4 hours during SDP1 and SDP2 wakefulness

This is test ability to stay awake in laboratory conditions conductive to falling asleep. The sleep onset latency is obtained during an electrophysiological test (EEG, EMG and EOG).

Once every 4 hours during SDP1 and SDP2 wakefulness
Change in number of inappropriate line crossings (driving performance) during extended wakefulness
Ramy czasowe: Once every 4 hours during SDP1 and SDP2 wakefulness

On the driving simulator the subjects will drive on a highway scenario representing a reconstruction of the real highway. Number of inappropriate line crossings (ILC) will mesured.

An ILC was recorded when the car crossed a right or left lateral lane marker, whatever the duration and the amplitude of the crossing. Exceptions were overtaking manoeuvres or some other necessary driving action.

Once every 4 hours during SDP1 and SDP2 wakefulness
Change in Standard deviation of the lateral position of the car (driving performance) during extended wakefulness
Ramy czasowe: Once every 4 hours during SDP1 and SDP2 wakefulness

On the driving simulator the subjects will drive on a highway scenario representing a reconstruction of the real highway. Standard deviation of the lateral position of the car (SDLP in cm) will mesured.

Lateral Position was defined as being 0 when the car was in the center of the lane, with positive value to the right and negative values to the left.

Once every 4 hours during SDP1 and SDP2 wakefulness
Change Sustained and selective attention during extended wakefulness
Ramy czasowe: Once every 4 hours during SDP1 and SDP2 wakefulness

The reaction time of subject to the presentation of a "target" stimulus (Continuous Performance Test, CPT)

Once every 4 hours during SDP1 and SDP2 wakefulness
Change in Vigilance during extended wakefulness
Ramy czasowe: Once every 4 hours during SDP1 and SDP2 wakefulness

The test examines the ability to concentrate and maintain attention over a long period (30mn) (TAP vigilance test)

Once every 4 hours during SDP1 and SDP2 wakefulness
Change in Simple reaction time test (PVT) during extended wakefulness
Ramy czasowe: 1 time every 4 hours during SDP1 and SDP2 wakefulness

Reaction-timed task that measures the consistency with which subjects respond to a visual stimulus.

1 time every 4 hours during SDP1 and SDP2 wakefulness
Change in conscious experience during extended wakefulness
Ramy czasowe: 5 assessments every 4 hours during SDP1 and SDP2 wakefulness

Questionnaire suggests participant's attention and thoughts were entirely focused on task-related stimuli

5 assessments every 4 hours during SDP1 and SDP2 wakefulness
Munich Chorotype Questionnaire
Ramy czasowe: Once time during inclusion. Visit V0

The Munich Chorotype Questionnaire (MCTQ) quantifies the chronotype according to the phase of entrainment based on the reported the mid-time of sleep; The MCTQ parameters are mid-sleep on weekdays (MSW in hr), mid-sleep on free days (MSF in hr) and mid-sleep on free days corrected for sleep debt on weekdays (MSFsc in hr). The MSFsc score (used as a chronotype indicator) represents a continuum of circadian preference, with an increasing tendency toward the evening type. MCTQ parameters are represented by hours, ranging from 0 hour (extreme morningness) to 12 hours (extreme eveningness).

Once time during inclusion. Visit V0
Horne and Ostberg morning/evening questionnaire (MEQ)
Ramy czasowe: Once time during inclusion. Visit V0

The Horne and Ostberg morning/evening questionnaire (MEQ) quantifies the chronotype.

The MEQ contains19 questions on life preferences (activity, sleep-wake cycle, meals) and the state of fatigue and drowsiness at certain times of the day. The MEQ score ranges from 16-86, with evening type ranging from16-41, neither or intermediate type from 42-58, and morning type from 59-86.

Once time during inclusion. Visit V0
Daydreaming frequency scale
Ramy czasowe: Once time during inclusion. Visit V0

To assess participants' general tendency to daydream in daily life

Once time during inclusion. Visit V0
Total sleep time (PSG)
Ramy czasowe: 2 times before SDP1 and SDP2

Total sleep time, the number of minutes asleep in bed after "lights off", will be calculated using a polysomnographic recording (PSG). EEG, EOG and EMG will be recorded during sleep.

2 times before SDP1 and SDP2
Sleep onset latency (PSG)
Ramy czasowe: 2 times before SDP1 and SDP2

Sleep onset latency, the minutes from lights off to sleep onset, will be calculated using a polysomnographic recording (PSG). EEG, EOG and EMG will be recorded during sleep.

2 times before SDP1 and SDP2
Sleep efficiency (PSG)
Ramy czasowe: 2 times before SDP1 and SDP2

Sleep efficiency, the ratio of the total time spent asleep (total sleep time) in a night compared to the total amount of time spent in bed, will be calculated using a polysomnographic recording (PSG). EEG, EOG and EMG will be recorded during sleep.

2 times before SDP1 and SDP2
Amount of sleep stages (PSG)
Ramy czasowe: 2 times before SDP1 and SDP2

Amount of N1,N2,N3 and R stage (expressed in p% of TST) will be calculated using a polysomnographic recording (PSG). EEG, EOG and EMG will be recorded during sleep.

2 times before SDP1 and SDP2
Wake after sleep onset (PSG)
Ramy czasowe: 2 times before SDP1 and SDP2

Wake after sleep onset, number of minutes scored as wake from sleep onset to the last minute scored as sleep while in bed, will be calculated using a polysomnographic recording (PSG). EEG, EOG and EMG will be recorded during sleep.

2 times before SDP1 and SDP2
Total sleep time (actigraphy)
Ramy czasowe: 2 times before SDP1 and SDP2

Total sleep time, the number of minutes asleep in bed after "lights off", will be calculated using an actigraph (wearable sleep test that tracks wrist movements)

2 times before SDP1 and SDP2
Sleep onset latency (actigraphy)
Ramy czasowe: 2 times before SDP1 and SDP2

Sleep onset latency, the minutes from lights off to sleep onset, will be calculated using an actigraph (wearable sleep test that tracks wrist movements)

2 times before SDP1 and SDP2
Sleep efficiency (actigraphy)
Ramy czasowe: 2 times before SDP1 and SDP2

Sleep efficiency, the ratio of the total time spent asleep (total sleep time) in a night compared to the total amount of time spent in bed will be calculated using an actigraph (wearable sleep test that tracks wrist movements)

2 times before SDP1 and SDP2
Wake after sleep onset (actigraphy)
Ramy czasowe: 2 times before SDP1 and SDP2

Wake after sleep onset, number of minutes scored as wake from sleep onset to the last minute scored as sleep while in bed will be calculated using an actigraph (wearable sleep test that tracks wrist movements)

2 times before SDP1 and SDP2

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Śledczy

  • Główny śledczy: Jean-Arthur Micoulaud-Franchi, MD/PhD, University Hospital, Bordeaux

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

8 marca 2023

Zakończenie podstawowe (Rzeczywisty)

23 maja 2025

Ukończenie studiów (Szacowany)

30 czerwca 2027

Daty rejestracji na studia

Pierwszy przesłany

14 czerwca 2022

Pierwszy przesłany, który spełnia kryteria kontroli jakości

6 lipca 2022

Pierwszy wysłany (Rzeczywisty)

12 lipca 2022

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

21 września 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

16 września 2026

Ostatnia weryfikacja

1 września 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj